GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments.

GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments. The British pharmaceutical giant said Wednesday that the 2.0 billion-pound ...

While the virus hasn’t made a sustained leap into humans, vaccines and treatments are being developed ahead of an outbreak.

GSK and the University of Oxford have joined hands to focus on the potential of cancer prevention through vaccination. The ...

Malaria kills more than a thousand children every day. Measures like antimalarial medications and insecticide-treated bed ...

British scientists are infecting a group of volunteers with a type of malaria that can cause relapses years after contracting it to study its long-term effects. Plasmodium vivax is carried by ...

Serum Institute of India CEO Adar Poonawalla spoke to NDTV on a range of issues, key among them the vaccine for malaria and other mosquito-borne diseases, on the sidelines of the World Economic ...

GlaxoSmithKline (GSK ... It’s not that the Gates Foundation is snubbing malaria vaccines — as one of Gavi’s biggest donors, Gates is helping to fund the R21 rollout. But rather than put ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

Influenza [strain A/H5N8] vaccine is under clinical development by GSK and currently in Phase II for Influenzavirus A Infections. According to GlobalData, Phase II drugs for Influenzavirus A ...

On the other hand, the malaria vaccine, developed in partnership with pharma giant GSK as part of a technology transfer agreement, will primarily be distributed to low- and middle-income countries ...